🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Hikma Pharmaceuticals shares target increased by Citi amid strong sector growth

EditorEmilio Ghigini
Published 2024-06-11, 05:00 a/m
HIK
-

On Tuesday, Citi updated its outlook on Hikma Pharmaceuticals (OTC:HKMPY) Plc (HIK:LN) (OTC: HKMPF) shares, increasing the price target to GBP28.45 from GBP27.70. The firm continues to endorse a Buy rating for the pharmaceutical company's stock. The revision follows a positive assessment of the latest industry data and the company's strategic initiatives.

Citi's analysis was influenced by IQVIA's April data, which showed robust growth trends for Hikma's Injectable and US Generics divisions. The Injectables sector in the US exhibited a 15% year-over-year growth and a 20% increase year-to-date.

The US Generics division, which accounts for 30% of sales and 20% of EBIT, is working towards a more stable business model with a target EBIT of $100-120 million. This goal is to be achieved through enhanced contract manufacturing and an expanded Specialty portfolio.

The firm also highlighted Hikma's Branded division, which is expected to contribute 24% of sales and 22% of EBIT by 2024 estimates. Efforts to refine the product mix in this division are anticipated to yield a significant rise in profitability.

Additionally, the Injectables business is projected to continue its high-single-digit growth with favorable margins. Hikma's foray into the US compounding market is also on track, with expectations to reach a break-even point by 2025.

Citi's revised price target is based on a net present value (NPV) approach, taking into account a more optimistic outlook for the Branded and Injectables divisions. The firm's estimates for earnings per share (EPS) compound annual growth rate (CAGR) from 2024 to 2029 are set at 12%, positioning Citi's projections 2-18% ahead of the consensus. The bull-bear valuation range provided by Citi spans from GBP33.6 to GBP18.1.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.